Bioventus Inc. Q3 2026 Earnings Recap

Bioventus shares fell 16.8% after earnings, with the most evident pressure point being softness in bone graft substitutes, down 6%, despite 3% overall revenue growth. The transcript also points to continued investment in growth initiatives, while the outlook details needed to assess the guidance update are not included.

Key Takeaways

• Q3 revenue grew 3%; pain treatments rose 6%, partly offset by a 6% decline in bone graft substitutes.
• PRP disposable-kit revenue exceeded capital-placement revenue for the first time, and the company secured exclusive sports-medicine rights for its PRP solution.
• PNS indicators improved: trial-to-permanent conversion exceeded plan, time to permanent placement shortened, and physicians trained increased by more than 50% quarter over quarter.
• Ultrasonics delivered double-digit revenue growth; international revenue rose 16%.
• Adjusted EBITDA margin was 20%, up 70 basis points year over year; management expects full-year margin to be above the prior-year level.